
Last year in the UK over 60,000 cancer patients enrolled on clinical trials aimed at improving cancer treatments and making them available to all.
Please note - this trial is no longer recruiting patients. We hope to add results when they are available.
This study is trying to find out why some people get high blood pressure when taking the drug pazopanib.
Pazopanib is a type of drug called a tyrosine kinase inhibitor (TKI for short). TKIs block tyrosine kinases, which are part of pathways that send messages telling cells to divide and grow. Blocking the effect of these tyrosine kinases may stop cancer cells growing.
A side effect of pazopanib can be a rise in blood pressure. Doctors want to find out more about why this happens to some people and not others. They want to find out if pazopanib affects the lining of veins and arteries (blood vessels) and if it is this that causes blood pressure to rise.
The aim of this study is to find out
You may be able to enter this trial if you
You cannot enter this trial if you
This trial will recruit 52 people. Everyone on the study will take pazopanib. You take pazopanib as a tablet once a day for 12 weeks in this trial. If test results show that it is working then you can continue to take it for longer.
The researchers will ask for a sample of your blood to use for research. If you do not want to give extra blood samples for this study, you don’t have to. You can still take part in the trial.
You see the doctors and have some tests before you start treatment. The tests include
You will be shown how to use a blood pressure machine at home and asked to record your blood pressure at different times during the study.
You visit the doctor at week 2 for an ECG, blood and urine tests. At week 3 you have a blood test. Then at week 4, and every 2 weeks afterwards, you have an ECG, blood and urine tests.
The trial team will do tests to look at blood flow through your veins and arteries during the study. These tests take about 3½ hours. They are painless but you do have to lie still for up to 2¼ hours. In one of the tests you have an injection of dye into an artery in your arm. The research team will explain exactly what you need to do for each test.
After 12 weeks of pazopanib you have an ECG, CT scan, MRI scan, blood pressure, blood tests and urine tests.
If the pazopanib has helped, you can continue to take it. Your cancer doctor will see you regularly for blood pressure and blood tests.
If the pazopanib has not helped, you stop taking it. The trial team will see you 4 weeks later for an ECG, blood pressure, blood and urine tests.
The most common side effects of pazopanib are
We have more information about the side effects of pazopanib.
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor Duncan Jodrell
Cambridge University Hospitals NHS Foundation Trust
Experimental Cancer Medicine Centre (ECMC)
GlaxoSmithKline (GSK)
NIHR Clinical Research Network: Cancer
NIHR Cambridge Biomedical Research Centre
University of Cambridge
Freephone 0808 800 4040
Last year in the UK over 60,000 cancer patients enrolled on clinical trials aimed at improving cancer treatments and making them available to all.